Lucie Peduto

Title: Lucie Peduto: Innovator in Cancer Therapy

Introduction

Lucie Peduto is a prominent inventor based in Paris, France. She has made significant contributions to the field of cancer therapy, particularly through her innovative research and patents. With a total of 3 patents, her work focuses on the use of specific inhibitors to enhance tumor treatments.

Latest Patents

One of her latest patents involves the use of inhibitors of ADAM12 as adjuvants in tumor therapies. This invention highlights the discovery that disrupting the stromal capsule can restore better vasculature and tumor perfusion, thereby improving T cell infiltration within melanoma tumors. The invention encompasses methods, compositions, and kits that utilize ADAM12 inhibitors to deplete ADAM12+ stromal cells in cancer patients, particularly when combined with anti-tumor compounds.

Another significant patent by Lucie Peduto addresses the use of ADAM12 inhibitors in preventing or treating inflammation-induced fibrosis. This invention identifies ADAM12 as a marker for inflammation-induced fibrosis and proposes the ablation of ADAM12-expressing cells as a therapeutic approach to combat the development of pro-fibrotic cells.

Career Highlights

Lucie has worked with esteemed institutions such as Institut Pasteur and the Institut National de la Santé et de la Recherche Médicale. Her research has been pivotal in advancing the understanding of cancer therapies and their applications.

Collaborations

Throughout her career, Lucie has collaborated with notable colleagues, including Gerard Eberl and Selene Di Carlo. These partnerships have further enriched her research and contributed to her innovative work in the field.

Conclusion

Lucie Peduto's contributions to cancer therapy through her patents and research are invaluable. Her innovative approaches to utilizing ADAM12 inhibitors demonstrate her commitment to advancing medical science and improving patient outcomes.